This fall
nearly 4,000 active cases are in two federal courts, and the vision-loss question is still open
In October 2026, Ozempic is fighting lawsuits on two federal fronts simultaneously. The main MDL (No. 3094) in the Eastern District of Pennsylvania now carries 3,848 active cases — plaintiffs claiming the drug caused gastroparesis, intestinal obstruction, and other gastrointestinal injuries, with failure-to-warn as the central theory. A separate MDL (No. 3163), carved out specifically for non-arteritic anterior ischemic optic neuropathy (NAION) — a form of sudden vision loss — has 146 active cases on a distinct track. In July 2026, Judge Karen Marston ruled that before bellwether trials begin, the court will first determine whether GLP-1 drugs can biologically cause NAION and whether federal law preempts the failure-to-warn claims entirely. Those proceedings are active this fall, in Q4 2026. The MDL machine is not an indictment of the drug. It is a legal structure designed to handle mass tort claims efficiently. But the combined caseload — nearly 4,000 complaints filed — signals that when a molecule becomes this culturally dominant this quickly, label adequacy and adverse event documentation face scrutiny at a scale clinical trials were never designed to anticipate.
The molecule
semaglutide mimics a gut hormone to suppress appetite — here is how it actually works
Semaglutide is a synthetic analog of glucagon-like peptide-1 (GLP-1), a 30-amino-acid incretin hormone secreted by L-cells in the small intestine in response to food. The endogenous hormone has a half-life of about two minutes — degraded almost instantly by dipeptidyl peptidase-4. Semaglutide replaces one amino acid (alanine at position 8, replaced with aminoisobutyric acid), adds a C18 fatty acid chain, and survives approximately one week in circulation. That pharmacokinetic engineering is the entire story of how a meal signal became a once-weekly injection. When semaglutide binds GLP-1 receptors in the pancreas, it augments glucose-dependent insulin secretion. When it binds receptors in the hypothalamus and brainstem, it modulates the satiety signal that tells the brain a meal is over. That second pathway — central appetite signaling — is where weight loss lives, and where the biology of both the weight-loss benefit and the gastrointestinal side effects originates. The nausea, the slowed gastric emptying, the satiety that outlasts the meal: these are the same mechanism expressed across different tissue targets. [PubMed literature on semaglutide and GLP-1 receptor pharmacology](https://pubmed.ncbi.nlm.nih.gov/?term=semaglutide+GLP-1+receptor+mechanism)
The pitch
ozempic became shorthand for effortless weight loss — the fda label says something narrower
The public story on semaglutide moved from 'diabetes drug' to 'the weight-loss shot celebrities use' to 'the drug that changes your relationship with food' in roughly three years. The telehealth prescriptions, the compounded knock-offs, the shortages — all of it reflects a genuine public conviction that this drug works in ways categorically different from previous weight-loss attempts. The conviction is not entirely wrong: semaglutide does produce clinically meaningful weight loss in people with obesity. But the public narrative extends well past the FDA label. Semaglutide is approved for adults with type 2 diabetes (Ozempic) and for adults with obesity or overweight with weight-related comorbidities (Wegovy). It is not approved as a general wellness tool, for weight loss below BMI thresholds, or as a preventive anti-aging intervention. The compounding shutdown — which ended legal access to most compounded semaglutide in April and May 2025, after courts rejected the industry challenge to the FDA's shortage-end declaration — reflects exactly this gap: a drug whose approved uses are specific but whose cultural moment is much broader. [FDA concerns with unapproved GLP-1 drugs used for weight loss](https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss)
What the data says
the step and select trials are among the most rigorous in weight-loss pharmacology — and the gastrointestinal risks are in the label
The evidence base for semaglutide is among the most robust in any pharmacological weight-management category. The STEP trial program (STEP 1 through 8) enrolled more than 10,000 participants across populations ranging from adults with obesity to people with type 2 diabetes to those with established cardiovascular disease. STEP 1, the pivotal obesity trial, showed an average 14.9% body weight reduction versus 2.4% for placebo over 68 weeks — the data that supported the Wegovy approval. The SELECT trial enrolled 17,604 adults with overweight or obesity and cardiovascular disease, showing a 20% reduction in major adverse cardiovascular events — the basis for additional cardiovascular risk-reduction labeling. [ClinicalTrials.gov records the full semaglutide STEP and SELECT trial program](https://clinicaltrials.gov/search?term=semaglutide+STEP+SELECT). At EASD 2026 in Milan in early October, Novo Nordisk presented real-world data from 636,525 adults with type 2 diabetes comparing semaglutide dose escalation against switching to tirzepatide; the [EASD 2026 Novo Nordisk data announcement](https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916767) reported a statistically significant cardiovascular outcome difference. The gastrointestinal side effects — nausea, vomiting, gastroparesis — are documented in the label, established in those same trials, and not scientifically contested. The NAION vision-loss question is different: whether GLP-1 receptor agonism carries a causal eye-risk that warranted earlier or stronger labeling is the scientific question a federal court is now being asked to help sort.
Approved — PeptideFactCheck stance
semaglutide is the most evidence-backed weight-loss molecule available — the lawsuits are testing label adequacy, not the trial data
Semaglutide holds PeptideFactCheck's Approved evidence tier — the highest classification used here — because regulatory approval for specific indications exists, backed by multiple large-scale clinical trial programs across diabetes, chronic weight management, and cardiovascular risk reduction. Approved means regulatory certainty for labeled uses, not a blank check for every claim the internet attaches to the molecule. The lawsuits in MDL 3094 and MDL 3163 do not change the evidence tier. They are legal proceedings testing the adequacy of warning labels and, in the NAION cases, the causal link between GLP-1 receptor agonism and a specific adverse event. If a court or a regulatory action finds that vision-loss risk was inadequately disclosed, the appropriate response is label revision — not withdrawal, and not a reassessment of the weight-loss and cardiovascular benefits that the STEP and SELECT programs established in controlled trials. What this October 2026 litigation snapshot tells the average reader is less dramatic than the case count implies: a transformative drug at population scale generates proportionally large legal challenges. The question the courts are sorting is whether specific adverse events were real, known, and adequately labeled. The [DailyMed prescribing information for semaglutide products](https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=semaglutide) is where the current regulatory record lives. Source trail before certainty.
Editorial boundary
What this page will not do
It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.